In vitro studies of a degradable device for controlled-release of meloxicam

被引:23
作者
Çetin, EÖ
Buduneli, N [1 ]
Atlihan, E
Kirilmaz, L
机构
[1] Ege Univ, Sch Dent, Dept Periodontol, TR-35100 Izmir, Turkey
[2] Ege Univ, Sch Pharm, Dept Biopharmaceut & Pharmacokinet, TR-35100 Izmir, Turkey
关键词
controlled drug delivery; gelatin matrix; meloxicam; periodontal disease; rate measurements;
D O I
10.1111/j.1600-051X.2005.00755.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background: Plaque biofilm and associated host responses are the primary factors in the pathogenesis of periodontitis. Delivery of medications directly into the periodontal pockets to suppress or eradicate the pathogenic microbiota or modulate the inflammatory response has attracted significant interest to limit periodontal tissue destruction. The aim of the present study was twofold: (1) to describe the development of a biodegradable controlled-release device containing meloxicam as the therapeutic agent and (2) to evaluate the in vitro release of meloxicam from this device into different release media. Methods: Films of cross-linked gelatin matrix containing meloxicam were prepared, hardened for various time periods and cut in a form to fit to the periodontal pocket anatomy. The release of active agents was studied separately in 10 ml distilled water, artificial saliva and pH 7.4 phosphate buffer at 37 degrees C. Apparatus Vibrax was used at 120 r.p.m. Determinations were carried out spectrophotometrically, and the release profiles were plotted as a function of time. The results were evaluated by the similarity test. Results: The release rates of meloxicam from the hardened (1h, 4h, 8 h) formulations were slower than the unhardened formulation in all the three release media. Increasing the hardening time decreased the release rates. The overall release rates were similar in artificial saliva and pH 7.4 phosphate buffer, while it was lower in distilled water. Conclusions: As a conclusion, cross-linked gelatin matrix films may be considered as a suitable inert material for obtaining a prolonged local release of meloxicam as an adjunct to the mechanical periodontal treatment. As required, further in vitro and in vivo studies will be performed before starting clinical applications of this controlled-release formulation of the anti-inflammatory agent.
引用
收藏
页码:773 / 777
页数:5
相关论文
共 27 条
[1]   Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats [J].
Bezerra, MM ;
de Lima, V ;
Alencar, VBM ;
Vieira, IB ;
Brito, GAC ;
Ribeiro, RA ;
Rocha, FAC .
JOURNAL OF PERIODONTOLOGY, 2000, 71 (06) :1009-1014
[2]   Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 [J].
Brooks, P ;
Emery, P ;
Evans, JF ;
Fenner, H ;
Hawkey, CJ ;
Patrono, C ;
Smolen, J ;
Breeveld, F ;
Day, R ;
Dougados, M ;
Ehrich, EW ;
Gijon-Baños, J ;
Kvien, TK ;
Van Rijswijk, MH ;
Warner, T ;
Zeidler, H .
RHEUMATOLOGY, 1999, 38 (08) :779-788
[3]   Gingival crevicular fluid matrix metalloproteinase-8 levels following adjunctive use of meloxicam and initial phase of periodontal therapy [J].
Buduneli, N ;
Vardar, S ;
Atilla, G ;
Sorsa, T ;
Luoto, H ;
Baylas, H .
JOURNAL OF PERIODONTOLOGY, 2002, 73 (01) :103-109
[4]  
BUDUNELI N, 2001, ANKARA U DISHEKIMLIG, V28, P161
[5]   In vitro studies on controlled-release cellulose acetate films for local delivery of chlorhexidine, indomethacin, and meloxicam [J].
Çetin, EÖ ;
Buduneli, N ;
Atlihan, E ;
Kirilmaz, L .
JOURNAL OF CLINICAL PERIODONTOLOGY, 2004, 31 (12) :1117-1121
[6]  
Engelhardt G, 1996, BRIT J RHEUMATOL, V35, P4
[7]  
Golub L M, 1992, Curr Opin Dent, V2, P80
[8]  
GOODSON J, 1989, J DENT RES, V68, P625
[9]  
*GUID IND, DISS TEST IMM REL SO
[10]   NONSTEROIDAL ANTIINFLAMMATORY DRUGS AS INHIBITORS OF PERIODONTAL-DISEASE PROGRESSION [J].
HOWELL, TH ;
WILLIAMS, RC .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1993, 4 (02) :177-196